Merck Zostava Shingles Vaccine Effective in Adults in Their 50s

(Reuters) - In a huge study aimed at broadening the use of Merck & Co's shingles vaccine, Zostavax reduced the incidence of the painful disease by 70 percent compared with a placebo in adults in their 50s, the company said.